<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02412852</url>
  </required_header>
  <id_info>
    <org_study_id>TheraVasc-TV1001-003</org_study_id>
    <nct_id>NCT02412852</nct_id>
  </id_info>
  <brief_title>A Phase 2a Study to Assess Safety &amp; Pharmacokinetics of Sustained Release Sodium Nitrite in Patients With Diabetic Pain</brief_title>
  <official_title>A Randomized, Double-blinded, Phase 2a Study to Assess the Safety and Pharmacokinetics of a Sustained Release Formulation of Sodium Nitrite (TV1001sr) in Patients With Diabetic Neuropathic Pain (DNP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TheraVasc Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kettering Health Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>TheraVasc Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, subjects with diabetic neuropathic pain (DNP) will be treated for 12 weeks
      with either placebo, 40 or 80 mg sustained release sodium nitrite (TV1001sr) twice daily.
      Primary endpoints will be safety and pharmacokinetics. Assessment of the study medications
      affects on pain following treatment will also be recorded.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a dose-ranging study to evaluate the safety, pharmacokinetics, and tolerability of
      multiple doses of an oral, sustained release formulation of sodium nitrite (TV1001sr) in
      subjects with DNP. The primary objective is to assess the safety and tolerability of multiple
      doses of twice daily 40 mg and 80 mg TV1001sr compared with placebo over a 12 week treatment
      period and the pharmacokinetics of the sustained release formulation of sodium nitrite.
      Secondary objectives are to evaluate the pharmacokinetics and markers of functional
      improvement including pain questionnaires, quantitative sensory testing and changes in
      markers of diabetes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 28, 2015</start_date>
  <completion_date type="Actual">April 3, 2017</completion_date>
  <primary_completion_date type="Actual">December 7, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reporting of Adverse Events During 12 Week Study Period</measure>
    <time_frame>12 weeks</time_frame>
    <description>The primary objective of this clinical study is to evaluate the safety and tolerability of multiple doses of twice daily 40mg and 80mg sustained release sodium nitrite compared with placebo over a 12 week treatment period. The following safety parameters will also be assessed: concomitant medication usage, physical examination, vital signs, Comprehensive Metabolic Panel, and complete blood count. Assessment of acute adverse events (i.e., drop in blood pressure, dizziness) after administration of each dose level. Counts are number of subjects reporting at least 1 Adverse Event. The total Adverse Events recorded in each cohort is also reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (Blood Levels of Nitrite)</measure>
    <time_frame>1 day</time_frame>
    <description>Blood levels of nitrite will be assessed for 6 hours post-administration on the initial dosing visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants Who Reported Use of Analgesic or Medications for Neuropathic Pain.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Daily patient reported use of analgesic or medications for neuropathic pain. The use of medications were recorded at the baseline visit and during both the intermediate and final visit for each subject. All subjects used at least one prescription pain medication, other than one subject in the 80-mg dose cohort who used only ibuprofen to control pain. Most subjects used more than one prescription pain medication. There was no change in use of pain medications during the trial period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Patients Reported Pain Through Composite Analysis of Pain Questionaires.</measure>
    <time_frame>Baseline (visit 1) and 12 weeks (visit 3)</time_frame>
    <description>Subjects completed the Brief pain inventory (BPI), RAND 36 questionnaire, neuropathic pain symptom inventory (NPSI) and Short Form McGill Pain Questionnaire at each visit for these self-reported questionnaires. The BPI is a questionnaire that measures the patient's subjective perception of pain, its exacerbating and alleviating factors, and perceived effect on functional status; the NPSI is a questionnaire that measures the symptoms associated with neuropathic pain; the Short Form McGill Questionnaire subjectively assesses the patients perception of pain described by commonly used adjectives associated with pain. NPSI is average of 12 questions, range from 0 (no pain) to 120 (maximal pain); For BPI severity and interference, questions are scored from 0-10, then there average score for each subsection is calculated (the higher the score, the worse the response); Scores on McGill range from 0-10, lower associated for less pain, then averaged for each sub score and total score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Assessment of Pain. (Quantitative Sensory Testing)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Quantitative sensory testing (QST) was conducted at each visit to determine patients sensitivity to pain. QST was assessed using a quantitative nerve conductance machine where nerves in the distal extremity are subjected to electrical stimulation to determine the sensory threshold of the skin. Nerve conductance measures how fast an electrical impulse moves through the nerve, and nerve velocity measures the speed at which an electrical impulse moves down a neuronal pathway.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Diabetes. (HbA1C Levels)</measure>
    <time_frame>12 weeks</time_frame>
    <description>HbA1C levels will be monitored at each visit to determine whether treatment reduces circulating glucose levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Blood Oxygenation. (Pulse Oximetry)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Pulse oximetry will be used at each visit to determine whether treatment improves oxygen levels in the blood.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One placebo tablet administered twice daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>40 mg TV1001sr</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One 40 mg enteric coated sustained release, sodium nitrite tablets administered twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (2)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two placebo tablets administered twice daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>80 mg TV1001sr</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two 40 mg enteric coated sustained release, sodium nitrite tablets administered twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium nitrite</intervention_name>
    <description>Sustained release formulation of sodium nitrite</description>
    <arm_group_label>40 mg TV1001sr</arm_group_label>
    <arm_group_label>80 mg TV1001sr</arm_group_label>
    <other_name>TV1001sr</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets containing same excipients and coatings used in the active tablets, without sodium nitrite being added.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Placebo (2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female subjects must be post-menopausal, sterilized or using suitable birth control

          -  Diagnosis of diabetes (HbA1c &gt; 6.0)

          -  Diagnosis of diabetic peripheral neuropathy pain in feet

          -  Presence of ongoing diabetic neuropathic for at least 3 months

          -  A pain score of greater than or equal to 4 on the Numerical Pain Rating Scale at
             screening

          -  Ability to provide written informed consent

        Exclusion Criteria:

          -  Patients with fibromyalgia or regional pain caused by lumbar or cervical compression

          -  History or diagnosis of significant neurological disease

          -  History and diagnosis of clinically significant psychiatric diseases

          -  Serious liver disease

          -  Poorly controlled diabetes

          -  Hypersensitivity to sodium nitrite or related compounds

          -  Life expectancy &lt; 6 months

          -  A chronic illness that may increase the risks associated with this study

          -  Active malignancy requiring active anti-neoplastic therapy that will, in the opinion
             of the investigator, interfere with study treatment or participation

          -  Pregnant or nursing women

          -  Current diagnosis of alcohol or other substance abuse

          -  Current use of sildenafil or other phosphodiesterase Type 5 Inhibitors

          -  History of methemoglobinemia, (met-Hb â‰¥ 15%)

          -  Subject is involved in litigation or receives worker's compensation

          -  Inability to speak English
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amol Soin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio Pain Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ohio Pain Clinic</name>
      <address>
        <city>Centerville</city>
        <state>Ohio</state>
        <zip>45458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 1, 2015</study_first_submitted>
  <study_first_submitted_qc>April 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2015</study_first_posted>
  <results_first_submitted>April 21, 2017</results_first_submitted>
  <results_first_submitted_qc>April 13, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 24, 2020</results_first_posted>
  <last_update_submitted>April 13, 2020</last_update_submitted>
  <last_update_submitted_qc>April 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neuropathy</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will only be available to the PI of the trial, summary information will be published and shared with other researchers.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>One placebo tablet administered twice daily for 12 weeks.
Placebo: Placebo tablets</description>
        </group>
        <group group_id="P2">
          <title>40 mg TV1001sr</title>
          <description>One 40 mg enteric coated sustained release, sodium nitrite tablets administered twice daily.
Sodium nitrite: Sustained release formulation of sodium nitrite</description>
        </group>
        <group group_id="P3">
          <title>Placebo (2)</title>
          <description>Two placebo tablets administered twice daily for 12 weeks.
Placebo: Placebo tablets</description>
        </group>
        <group group_id="P4">
          <title>80 mg TV1001sr</title>
          <description>Two 40 mg enteric coated sustained release, sodium nitrite tablets administered twice daily.
Sodium nitrite: Sustained release formulation of sodium nitrite</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>One placebo tablet administered twice daily for 12 weeks.
Placebo: Placebo tablets</description>
        </group>
        <group group_id="B2">
          <title>40 mg TV1001sr</title>
          <description>One 40 mg enteric coated sustained release, sodium nitrite tablets administered twice daily.
Sodium nitrite: Sustained release formulation of sodium nitrite</description>
        </group>
        <group group_id="B3">
          <title>Placebo (2)</title>
          <description>Two placebo tablets administered twice daily for 12 weeks.
Placebo: Placebo tablets</description>
        </group>
        <group group_id="B4">
          <title>80 mg TV1001sr</title>
          <description>Two 40 mg enteric coated sustained release, sodium nitrite tablets administered twice daily.
Sodium nitrite: Sustained release formulation of sodium nitrite</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reporting of Adverse Events During 12 Week Study Period</title>
        <description>The primary objective of this clinical study is to evaluate the safety and tolerability of multiple doses of twice daily 40mg and 80mg sustained release sodium nitrite compared with placebo over a 12 week treatment period. The following safety parameters will also be assessed: concomitant medication usage, physical examination, vital signs, Comprehensive Metabolic Panel, and complete blood count. Assessment of acute adverse events (i.e., drop in blood pressure, dizziness) after administration of each dose level. Counts are number of subjects reporting at least 1 Adverse Event. The total Adverse Events recorded in each cohort is also reported.</description>
        <time_frame>12 weeks</time_frame>
        <population>Randomized population including dropouts.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Placebo</title>
            <description>A combination of the once/day and twice/day placebo groups.</description>
          </group>
          <group group_id="O2">
            <title>40 mg TV1001sr</title>
            <description>Treatment twice daily with 40 mg sustained release sodium nitrite</description>
          </group>
          <group group_id="O3">
            <title>80 mg TV1001sr</title>
            <description>Treatment with 80 mg (2 x 40 mg tablets) twice daily with sustained release sodium nitrite</description>
          </group>
        </group_list>
        <measure>
          <title>Reporting of Adverse Events During 12 Week Study Period</title>
          <description>The primary objective of this clinical study is to evaluate the safety and tolerability of multiple doses of twice daily 40mg and 80mg sustained release sodium nitrite compared with placebo over a 12 week treatment period. The following safety parameters will also be assessed: concomitant medication usage, physical examination, vital signs, Comprehensive Metabolic Panel, and complete blood count. Assessment of acute adverse events (i.e., drop in blood pressure, dizziness) after administration of each dose level. Counts are number of subjects reporting at least 1 Adverse Event. The total Adverse Events recorded in each cohort is also reported.</description>
          <population>Randomized population including dropouts.</population>
          <units>Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects reporting at least one Adverse Event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Adverse Events reported in each cohort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (Blood Levels of Nitrite)</title>
        <description>Blood levels of nitrite will be assessed for 6 hours post-administration on the initial dosing visit.</description>
        <time_frame>1 day</time_frame>
        <population>All subjects who were randomized.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Placebo</title>
            <description>A combination of the once/day and twice/day placebo groups.</description>
          </group>
          <group group_id="O2">
            <title>40 mg TV1001sr</title>
            <description>Treatment twice daily with 40 mg sustained release sodium nitrite</description>
          </group>
          <group group_id="O3">
            <title>80 mg TV1001sr</title>
            <description>Treatment with 80 mg (2 x 40 mg tablets) twice daily with sustained release sodium nitrite</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (Blood Levels of Nitrite)</title>
          <description>Blood levels of nitrite will be assessed for 6 hours post-administration on the initial dosing visit.</description>
          <population>All subjects who were randomized.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1399" spread="47"/>
                    <measurement group_id="O2" value="9699" spread="10199"/>
                    <measurement group_id="O3" value="9905" spread="12383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <other_analysis_desc>]The pharmacokinetics data are particularly sparse, and therefore substantial interpolations and imputations were required to produce an analyzable data set. Consequently, while not ideal, the Last Observation Carried Forward method was used for these data. There was a large amount of missing data which required imputation to determine results. The large amount of interpolations and imputations required for the pharmacokinetic analysis means that the pharmacokinetic results will need to be interpreted with caution. 3 X 3 Analysis of Variance used to compare Placebo to the two active groups. Missing data required imputation of available data.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Participants Who Reported Use of Analgesic or Medications for Neuropathic Pain.</title>
        <description>Daily patient reported use of analgesic or medications for neuropathic pain. The use of medications were recorded at the baseline visit and during both the intermediate and final visit for each subject. All subjects used at least one prescription pain medication, other than one subject in the 80-mg dose cohort who used only ibuprofen to control pain. Most subjects used more than one prescription pain medication. There was no change in use of pain medications during the trial period.</description>
        <time_frame>12 weeks</time_frame>
        <population>Analyzed only those subjects who completed 12 weeks of testing.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Placebo</title>
            <description>A combination of the once/day and twice/day placebo groups.</description>
          </group>
          <group group_id="O2">
            <title>40 mg TV1001sr</title>
            <description>Treatment twice daily with 40 mg sustained release sodium nitrite</description>
          </group>
          <group group_id="O3">
            <title>80 mg TV1001sr</title>
            <description>Treatment with 80 mg (2 x 40 mg tablets) twice daily with sustained release sodium nitrite</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants Who Reported Use of Analgesic or Medications for Neuropathic Pain.</title>
          <description>Daily patient reported use of analgesic or medications for neuropathic pain. The use of medications were recorded at the baseline visit and during both the intermediate and final visit for each subject. All subjects used at least one prescription pain medication, other than one subject in the 80-mg dose cohort who used only ibuprofen to control pain. Most subjects used more than one prescription pain medication. There was no change in use of pain medications during the trial period.</description>
          <population>Analyzed only those subjects who completed 12 weeks of testing.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects using any medicine to treat pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects using Gabapentin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects using Lyrica</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects using Morphine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects using Tramadol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects using Cymbalta</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects using Flexeril</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects using Naproxen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects using Percocet</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects using Vicodin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Patients Reported Pain Through Composite Analysis of Pain Questionaires.</title>
        <description>Subjects completed the Brief pain inventory (BPI), RAND 36 questionnaire, neuropathic pain symptom inventory (NPSI) and Short Form McGill Pain Questionnaire at each visit for these self-reported questionnaires. The BPI is a questionnaire that measures the patient's subjective perception of pain, its exacerbating and alleviating factors, and perceived effect on functional status; the NPSI is a questionnaire that measures the symptoms associated with neuropathic pain; the Short Form McGill Questionnaire subjectively assesses the patients perception of pain described by commonly used adjectives associated with pain. NPSI is average of 12 questions, range from 0 (no pain) to 120 (maximal pain); For BPI severity and interference, questions are scored from 0-10, then there average score for each subsection is calculated (the higher the score, the worse the response); Scores on McGill range from 0-10, lower associated for less pain, then averaged for each sub score and total score.</description>
        <time_frame>Baseline (visit 1) and 12 weeks (visit 3)</time_frame>
        <population>NPS is a sum of total scores, McGill and BPI an average of the scores for each question.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Placebo</title>
            <description>A combination of the once/day and twice/day placebo groups.</description>
          </group>
          <group group_id="O2">
            <title>40 mg TV1001sr</title>
            <description>Treatment twice daily with 40 mg sustained release sodium nitrite</description>
          </group>
          <group group_id="O3">
            <title>80 mg TV1001sr</title>
            <description>Treatment with 80 mg (2 x 40 mg tablets) twice daily with sustained release sodium nitrite</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Patients Reported Pain Through Composite Analysis of Pain Questionaires.</title>
          <description>Subjects completed the Brief pain inventory (BPI), RAND 36 questionnaire, neuropathic pain symptom inventory (NPSI) and Short Form McGill Pain Questionnaire at each visit for these self-reported questionnaires. The BPI is a questionnaire that measures the patient's subjective perception of pain, its exacerbating and alleviating factors, and perceived effect on functional status; the NPSI is a questionnaire that measures the symptoms associated with neuropathic pain; the Short Form McGill Questionnaire subjectively assesses the patients perception of pain described by commonly used adjectives associated with pain. NPSI is average of 12 questions, range from 0 (no pain) to 120 (maximal pain); For BPI severity and interference, questions are scored from 0-10, then there average score for each subsection is calculated (the higher the score, the worse the response); Scores on McGill range from 0-10, lower associated for less pain, then averaged for each sub score and total score.</description>
          <population>NPS is a sum of total scores, McGill and BPI an average of the scores for each question.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NPSI: Total-V1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.4" lower_limit="7" upper_limit="75"/>
                    <measurement group_id="O2" value="34.7" lower_limit="18" upper_limit="80"/>
                    <measurement group_id="O3" value="56.0" lower_limit="21" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NPSI: Total-V3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.4" lower_limit="9" upper_limit="81"/>
                    <measurement group_id="O2" value="30.0" lower_limit="0" upper_limit="76"/>
                    <measurement group_id="O3" value="46.0" lower_limit="6" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BPI: Severity Score-V1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="1.25" upper_limit="7.5"/>
                    <measurement group_id="O2" value="4.3" lower_limit="1.25" upper_limit="8.5"/>
                    <measurement group_id="O3" value="5.9" lower_limit="2.5" upper_limit="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BPI: Severity Score-V3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" lower_limit="1.5" upper_limit="7.8"/>
                    <measurement group_id="O2" value="3.8" lower_limit="0.8" upper_limit="8.8"/>
                    <measurement group_id="O3" value="5.1" lower_limit="2.0" upper_limit="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BPI: Interferrence-V1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="0.0" upper_limit="9.7"/>
                    <measurement group_id="O2" value="4.4" lower_limit="0.7" upper_limit="7.9"/>
                    <measurement group_id="O3" value="6.4" lower_limit="2.0" upper_limit="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BPI: Interferrence-V3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="0.0" upper_limit="10.0"/>
                    <measurement group_id="O2" value="4.2" lower_limit="1.1" upper_limit="8.6"/>
                    <measurement group_id="O3" value="5.7" lower_limit="3.1" upper_limit="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>McGill: Total-V1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="1.1" upper_limit="9.1"/>
                    <measurement group_id="O2" value="3.9" lower_limit="1.8" upper_limit="7.6"/>
                    <measurement group_id="O3" value="4.8" lower_limit="1.7" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>McGill: Total-V3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="0.4" upper_limit="7.5"/>
                    <measurement group_id="O2" value="2.5" lower_limit="0.5" upper_limit="7.2"/>
                    <measurement group_id="O3" value="4.6" lower_limit="0.5" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>McGill: Continuous-V1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="1.0" upper_limit="9.0"/>
                    <measurement group_id="O2" value="3.7" lower_limit="0.9" upper_limit="7.2"/>
                    <measurement group_id="O3" value="4.4" lower_limit="0.5" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>McGill: Continuous-V3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="0.0" upper_limit="6.6"/>
                    <measurement group_id="O2" value="1.9" lower_limit="0.0" upper_limit="5.8"/>
                    <measurement group_id="O3" value="4.3" lower_limit="0.7" upper_limit="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>McGill: Intermittent-V1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="0.0" upper_limit="9.7"/>
                    <measurement group_id="O2" value="4.6" lower_limit="2.3" upper_limit="8.5"/>
                    <measurement group_id="O3" value="5.9" lower_limit="0.3" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>McGill: Intermittent-V3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="0.0" upper_limit="9.2"/>
                    <measurement group_id="O2" value="2.8" lower_limit="0.0" upper_limit="8.3"/>
                    <measurement group_id="O3" value="5.3" lower_limit="0.0" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>ANOVA on only those subjects who completed testing.</non_inferiority_desc>
            <p_value>0.05</p_value>
            <p_value_desc>The results were analyzed using an ANOVA with one between-subjects factor (Group: both placebo groups combined, 40 mg TV1001sr, and 80 mg TV1001sr); and one within-subjects factor (Visit: Visit 1, Visit 2, and Visit 3).</p_value_desc>
            <method>ANOVA</method>
            <method_desc>The means of the three groups were further analyzed using a post hoc comparison procedure (the ScheffÃ© test).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Assessment of Pain. (Quantitative Sensory Testing)</title>
        <description>Quantitative sensory testing (QST) was conducted at each visit to determine patients sensitivity to pain. QST was assessed using a quantitative nerve conductance machine where nerves in the distal extremity are subjected to electrical stimulation to determine the sensory threshold of the skin. Nerve conductance measures how fast an electrical impulse moves through the nerve, and nerve velocity measures the speed at which an electrical impulse moves down a neuronal pathway.</description>
        <time_frame>12 weeks</time_frame>
        <population>Analyzed only the subjects that completed testing.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Placebo</title>
            <description>A combination of the once/day and twice/day placebo groups.</description>
          </group>
          <group group_id="O2">
            <title>40 mg TV1001sr</title>
            <description>Treatment twice daily with 40 mg sustained release sodium nitrite</description>
          </group>
          <group group_id="O3">
            <title>80 mg TV1001sr</title>
            <description>Treatment with 80 mg (2 x 40 mg tablets) twice daily with sustained release sodium nitrite</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Assessment of Pain. (Quantitative Sensory Testing)</title>
          <description>Quantitative sensory testing (QST) was conducted at each visit to determine patients sensitivity to pain. QST was assessed using a quantitative nerve conductance machine where nerves in the distal extremity are subjected to electrical stimulation to determine the sensory threshold of the skin. Nerve conductance measures how fast an electrical impulse moves through the nerve, and nerve velocity measures the speed at which an electrical impulse moves down a neuronal pathway.</description>
          <population>Analyzed only the subjects that completed testing.</population>
          <units>meters per second</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nerve Conductance: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="1.4"/>
                    <measurement group_id="O2" value="3.4" spread="0.7"/>
                    <measurement group_id="O3" value="6.0" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nerve Conductance: V2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="1.8"/>
                    <measurement group_id="O2" value="3.1" spread="0.9"/>
                    <measurement group_id="O3" value="5.2" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nerve Conductance: V3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="1.2"/>
                    <measurement group_id="O2" value="3.2" spread="0.6"/>
                    <measurement group_id="O3" value="4.2" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nerve Velocity: Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.7" spread="6.5"/>
                    <measurement group_id="O2" value="41.1" spread="4.3"/>
                    <measurement group_id="O3" value="39.4" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nerve Velocity: V2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.1" spread="5.3"/>
                    <measurement group_id="O2" value="39.3" spread="7.8"/>
                    <measurement group_id="O3" value="42.3" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nerve Velocity: V3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.2" spread="6.4"/>
                    <measurement group_id="O2" value="37.7" spread="3.2"/>
                    <measurement group_id="O3" value="46.8" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The composite conduction measure and the composite velocity measure were analyzed using an Analysis of Variance with one between-subjects factor (Group: combined placebo, 40 mg TV1001, and 80 mg TV1001); and one within-subjects factor (Visit: Visit 1, Visit 2, and Visit 3).</non_inferiority_desc>
            <p_value>.15</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Diabetes. (HbA1C Levels)</title>
        <description>HbA1C levels will be monitored at each visit to determine whether treatment reduces circulating glucose levels.</description>
        <time_frame>12 weeks</time_frame>
        <population>HbA1c blood levels were analyzed at baseline, V2 and V3</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Placebo</title>
            <description>A combination of the once/day and twice/day placebo groups.</description>
          </group>
          <group group_id="O2">
            <title>40 mg TV1001sr</title>
            <description>Treatment twice daily with 40 mg sustained release sodium nitrite</description>
          </group>
          <group group_id="O3">
            <title>80 mg TV1001sr</title>
            <description>Treatment with 80 mg (2 x 40 mg tablets) twice daily with sustained release sodium nitrite</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Diabetes. (HbA1C Levels)</title>
          <description>HbA1C levels will be monitored at each visit to determine whether treatment reduces circulating glucose levels.</description>
          <population>HbA1c blood levels were analyzed at baseline, V2 and V3</population>
          <units>percentage of glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="1.4"/>
                    <measurement group_id="O2" value="7.7" spread="1.2"/>
                    <measurement group_id="O3" value="8.5" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="1.2"/>
                    <measurement group_id="O2" value="7.4" spread="0.9"/>
                    <measurement group_id="O3" value="7.9" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" spread="2.0"/>
                    <measurement group_id="O2" value="7.7" spread="1.6"/>
                    <measurement group_id="O3" value="8.2" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A 3 by 3 Analysis of Variance with one between-subjects factor (Combined placebo, 40 mg TV1001, or 80 mg TV1001) and one within-subjects factor (Visit 1, Visit 2, or Visit 3) was performed for HbA1c values.</non_inferiority_desc>
            <p_value>.36</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Blood Oxygenation. (Pulse Oximetry)</title>
        <description>Pulse oximetry will be used at each visit to determine whether treatment improves oxygen levels in the blood.</description>
        <time_frame>12 weeks</time_frame>
        <population>Oxygen saturation was measured at baseline, V2 and V3.</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Placebo</title>
            <description>A combination of the once/day and twice/day placebo groups.</description>
          </group>
          <group group_id="O2">
            <title>40 mg TV1001sr</title>
            <description>Treatment twice daily with 40 mg sustained release sodium nitrite</description>
          </group>
          <group group_id="O3">
            <title>80 mg TV1001sr</title>
            <description>Treatment with 80 mg (2 x 40 mg tablets) twice daily with sustained release sodium nitrite</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Blood Oxygenation. (Pulse Oximetry)</title>
          <description>Pulse oximetry will be used at each visit to determine whether treatment improves oxygen levels in the blood.</description>
          <population>Oxygen saturation was measured at baseline, V2 and V3.</population>
          <units>% Oxygenation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7" spread="2.6"/>
                    <measurement group_id="O2" value="95.6" spread="2.3"/>
                    <measurement group_id="O3" value="96.3" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0" spread="3.0"/>
                    <measurement group_id="O2" value="96.4" spread="2.2"/>
                    <measurement group_id="O3" value="95.3" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.2" spread="2.8"/>
                    <measurement group_id="O2" value="96.0" spread="2.4"/>
                    <measurement group_id="O3" value="95.1" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>ANOVA to compare differences from baseline to completion of testing.</non_inferiority_desc>
            <p_value>.93</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>9 months</time_frame>
      <desc>Asked subjects at each phone call and visit to report any adverse event.</desc>
      <group_list>
        <group group_id="E1">
          <title>Combined Placebo</title>
          <description>A combination of the once/day and twice/day placebo groups.</description>
        </group>
        <group group_id="E2">
          <title>40 mg TV1001sr</title>
          <description>Treatment twice daily with 40 mg sustained release sodium nitrite</description>
        </group>
        <group group_id="E3">
          <title>80 mg TV1001sr</title>
          <description>Treatment with 80 mg (2 x 40 mg tablets) twice daily with sustained release sodium nitrite</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pains</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ulcers</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Numbness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tony Giordano</name_or_title>
      <organization>TheraVasc Inc.</organization>
      <phone>3183493851</phone>
      <email>tgiordano@theravasc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

